Myocardial Stunning During Severe Systemic Inflammation: A Comprehensive Review

Abstract

Myocardial stunning, characterized by transient left ventricular dysfunction with preserved myocardial viability, is increasingly recognized as a critical cardiac complication during episodes of severe systemic inflammation. This review provides an evidence-based exploration of the epidemiology, pathophysiology, risk factors, clinical features, diagnostic challenges, and therapeutic approaches related to myocardial stunning in settings such as sepsis, systemic inflammatory response syndrome (SIRS), and cytokine storm syndromes. Emphasis is placed on recent advances, practical clinical insights, and guideline-directed management strategies for healthcare professionals dealing with critically ill patients.

Introduction

Systemic inflammation, whether due to infectious or non-infectious etiologies, can precipitate acute cardiovascular dysfunction with significant morbidity and mortality. Myocardial stunning—a reversible form of cardiac dysfunction—has emerged as a hallmark finding in severe systemic inflammatory states like sepsis and SIRS. Despite preserved coronary perfusion, affected patients display transient myocardial contractile impairment. Understanding the mechanistic basis, clinical implications, and management of myocardial stunning in this context is essential for optimizing outcomes in critically ill populations.

Epidemiology / Disease Burden

Myocardial stunning is reported in up to 40–60% of patients with septic shock, making it a common but often under-recognized complication in intensive care units (ICUs). The true prevalence may be underestimated, given variability in diagnostic criteria and reliance on advanced imaging modalities. Systemic inflammation-induced myocardial dysfunction contributes to increased ICU length of stay, higher vasopressor requirements, and elevated short-term mortality. The burden is particularly high among elderly patients, those with pre-existing cardiac disease, and populations exposed to novel systemic inflammatory triggers such as COVID-19.

Pathophysiology

Myocardial stunning during systemic inflammation is multifactorial. Key mechanisms include the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), which directly depress myocardial contractility. Nitric oxide (NO) overproduction, mitochondrial dysfunction, and oxidative stress further impair energy utilization and calcium handling in myocytes. Additionally, microvascular dysfunction and endothelial activation disrupt myocardial perfusion, while catecholamine excess exacerbates myocardial oxygen demand and arrhythmogenic risk. Importantly, these changes occur without irreversible myocyte necrosis, distinguishing stunning from infarction.

Risk Factors

Established risk factors for myocardial stunning in systemic inflammation include advanced age, pre-existing cardiovascular disease, diabetes mellitus, chronic kidney disease, and prior exposure to cardiotoxic agents. The intensity and duration of systemic inflammation, as reflected by high cytokine levels and persistent hypotension, are strong predictors. Genetic predispositions affecting inflammatory responses and myocardial resilience may also play a role, as suggested by emerging translational research.

Clinical Features

Clinically, myocardial stunning manifests as acute left ventricular systolic dysfunction, often presenting with hypotension, oliguria, or overt cardiogenic shock in the context of severe inflammation. On examination, patients may have signs of pulmonary congestion, elevated jugular venous pressure, and diminished peripheral perfusion. Arrhythmias, particularly atrial fibrillation and ventricular ectopy, are common. Importantly, these features are often masked by the systemic inflammatory state, necessitating a high index of suspicion among clinicians.

Diagnosis

Diagnosis relies on echocardiographic assessment, revealing global or regional hypokinesis with normal or mildly reduced coronary flow. Cardiac biomarkers such as troponin and natriuretic peptides may be modestly elevated but are not specific. Advanced imaging (e.g., cardiac MRI with late gadolinium enhancement) can help exclude myocardial infarction and assess viability. Laboratory evidence of systemic inflammation (elevated CRP, procalcitonin, cytokines) supports the diagnosis. Differential diagnoses—such as myocarditis, ischemic injury, and Takotsubo cardiomyopathy—must be considered and excluded where feasible.

Treatment & Management

Management is primarily supportive, focusing on reversing the underlying systemic inflammatory process. Early goal-directed therapy in sepsis, source control of infection, and judicious use of fluids and vasopressors are cornerstone interventions. Inotropic agents (e.g., dobutamine) may be required for severe LV dysfunction refractory to vasopressors. Mechanical circulatory support (e.g., intra-aortic balloon pump, ECMO) is reserved for refractory cardiogenic shock. Careful avoidance of volume overload and myocardial depressant drugs is essential. Close hemodynamic monitoring and individualized titration of therapy are recommended.

Recent Advances / Emerging Therapies

Recent advances focus on targeted immunomodulation and myocardial protection. Agents such as IL-6 inhibitors (tocilizumab), corticosteroids, and selective nitric oxide synthase inhibitors have shown promise in reducing myocardial dysfunction during cytokine storm syndromes. Beta-blockers and levosimendan are under investigation for their potential to improve cardiac efficiency and mitigate arrhythmias. Biomarker-guided therapy and advanced hemodynamic monitoring tools are enhancing personalized management strategies in the ICU. Ongoing research into mitochondrial-targeted therapies offers hope for more definitive interventions in the future.

Guideline Recommendations

Current guidelines from societies such as the Surviving Sepsis Campaign and the American Heart Association recommend prompt identification and supportive care for cardiac dysfunction in systemic inflammation. Echocardiography is endorsed for all patients with hemodynamic instability. Routine use of beta-blockers or immunomodulatory therapies remains investigational and should be considered on a case-by-case basis. Multidisciplinary care involving intensivists, cardiologists, and infectious disease specialists is strongly advised.

Conclusion

Myocardial stunning is a clinically significant and potentially reversible complication of severe systemic inflammation. Timely recognition, comprehensive diagnostic evaluation, and evidence-based supportive management are critical for improving outcomes in affected patients. Emerging therapies targeting the inflammatory cascade and mitochondrial dysfunction represent promising directions for future research and clinical innovation. Ongoing vigilance and adherence to guideline recommendations will remain essential as the understanding of this complex syndrome continues to evolve.